Medicines Optimisation
Hello reader.

Unlicensed Medicines for Children - Use Standard Strengths

The Neonatal and Paediatric Pharmacists’ Group (NPPG) and the Royal College of Paediatrics and Child Health (RCPCH) have issued a joint statement on using standardised strengths of unlicensed liquid medicines in children. The two bodies strongly recommend that when children require unlicensed liquid medications, they should receive the RCPCH- and NPPG- recommended strength, where one exists. There are currently 17 such recommended …

Read more

NICE Key Therapeutic Topics - 2019 Update

NICE have updated and revised several Key Therapeutic Topic (KTT) documents and added two new topics to the KTT collection of evidence summaries to support medicines optimisation: KTT5 Asthma: medicines safety priorities UPDATE KTT6 Hypnotics UPDATE KTT7 Antipsychotics in people living with dementia UPDATE KTT9 Antimicrobial stewardship- prescribing antibiotics UPDATE KTT12 Type 2 diabetes mellitus: medicines optimisation priorities UPDATE KTT14 …

Read more

Fluoroquinolone antibiotics - Safety Concerns

Fluoroquinolone antibiotics, such as ciprofloxacin, have a limited place in NICE & Public Health England guidance on managing common infections. Fluoroquinolones may be first line options for treatment of acute prostatitis, epidydimitis,  gonorrhoea & acute pyelonephritis, and second choice options for LRTI, catheter associated LUTI and pelvic inflammatory disease - depending on bacterial susceptibilities and taking account of safety issues. …

Read more

SGLT2 inhibitors - reports of Fournier's gangrene

The MHRA have provided the following advice arising from reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum)  - a rare but serious and potentially life-threatening infection - in association with use of sodium-glucose co-transporter 2 (SGLT2) inhibitors: if Fournier’s gangrene is suspected, stop the SGLT2 inhibitor and urgently start treatment (including antibiotics and surgical debridement as required) …

Read more

Carbimazole - Stronger Advice on Contraception

The MHRA has strengthened advice for healthcare professionals on contraception requirements for women with childbearing potential prescribed carbimazole. The stronger guidance recommends following advice provided in the FSRH statement on contraception for women using known teratogenic drugs or drugs with potential teratogenic effects. The FSRH statement recommends that women at risk should always be advised to use highly effective contraception, …

Read more

Yellow Card App - Updated & Improved

The MHRA have updated and improved the Yellow Card App for iOS and Android. The App allows users to: Report suspected side effects to medicines (including vaccines, herbal products and homeopathic remedies) Track new safety information published by the MHRA about medicines Create a watchlist for alerts to medicines of interest to you View numbers of reports received by the MHRA …

Read more

Tapentadol - Risk of Seizures & Serotonin Syndrome

Following an EU-wide review of safety data and spontaneous reports of serious adverse events, European & UK regulators have strengthened warnings about the risks of both seizures and serotonin syndrome associated with the tramadol-like opioid tapentadol. Regulators have provided the following advice for Healthcare Professionals: tapentadol, like all opioid medicines, can induce seizures tapentadol should be prescribed with care in patients …

Read more